Suppression of frequency of chronic myelogenous leukemia progenitors compared with reduction in proliferation and viability
| Assay . | Primitive progenitors (% decrease) . | Committed progenitors (% decrease) . |
|---|---|---|
| Progenitor frequency | 43 ± 12 | 52 ± 5 |
| Proliferation inhibition | 61 ± 2 | 34 ± 5 |
| Viability decrease | 5 ± 3 | 5 ± 3 |
| Assay . | Primitive progenitors (% decrease) . | Committed progenitors (% decrease) . |
|---|---|---|
| Progenitor frequency | 43 ± 12 | 52 ± 5 |
| Proliferation inhibition | 61 ± 2 | 34 ± 5 |
| Viability decrease | 5 ± 3 | 5 ± 3 |
Values are the mean ± SEM percentage decrease in the different variables for progenitor cells exposed to 1 μM imatinib mesylate for 96 hours compared with cells with a similar incubation but without imatinib mesylate.